Title of article
Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model
Author/Authors
Koto، نويسنده , , Kazutaka and Horie، نويسنده , , Naoyuki and Kimura، نويسنده , , Shinya and Murata، نويسنده , , Hiroaki and Sakabe، نويسنده , , Tomoya and Matsui، نويسنده , , Takaaki and Watanabe، نويسنده , , Motonobu and Adachi، نويسنده , , Souichi and Maekawa، نويسنده , , Taira and Fushiki، نويسنده , , Shinji and Kubo، نويسنده , , Toshikazu، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2009
Pages
8
From page
271
To page
278
Abstract
Clinically obtainable concentrations of zoledronic acid (ZOL) inhibited the production of vascular endothelial growth factor and reduced the migration, adhesion, and invasiveness of osteosarcoma (OS) cells in vitro. The in vivo effects of ZOL were investigated by using a murine model of spontaneous lung metastasis. The higher dose of ZOL (80 μg/kg three times/week) inhibited the growth of OS at the primary site, accompanied by inhibition of neovascularization in the tumor. Interestingly, while the lower dose of ZOL (80 μg/kg once a week) could not inhibit the growth of OS at the primary site, it significantly prevented lung metastasis.
Keywords
Zoledronic acid , Osteosarcoma , metastasis , Neovascularization
Journal title
Cancer Letters
Serial Year
2009
Journal title
Cancer Letters
Record number
1813458
Link To Document